Aromatase Inhibitors In Neoadjuvant Endocrine Therapy With Breast Cancer:A Meta-Analysis

Objective Evaluation the efficacy and safety of aromatase inhibitors(AIs) applied in neoadjuvant endocrine therapy of postmenopausal patients with hormone-dependent breast cancer.Methods computer retrieval the Cochrane library, PubMed, CNKI and CBMdisc database with established standards into randomized controlled trials of neoadjuvant endocrine therapy using the aromatase inhibitors, with the quality evaluation by Cochrane system, extracted data, and system analysis with the Rev Man 5.0 software.Results 9 randomized controlled trials is incorporated,with 1512 patients, results of meta analysis;(1)The total effective rate and complete response rates of AIs were superior by estrogen receptor blockers in the neoadjuvant endocrine therapy of breast cancer(2) The neoadjuvant endocrine treatment with AIs can attach a equal level of the curative effect with neoadjuvant chemotherapy in the hormone dependency breast cancer patients;(3)New adjuvant chemotherapy combined with new adjuvant endocrine therapy might be better in the near future curative effect for hormone dependency breast cancer patients, but argumentation intensity is not high because of too little research(4)AIs and tamoxifen have a lower incidence of adverse reaction and a lighter symptom compared with the cytotoxic drugs,.Conclusion Neoadjuvant therapy with AIs is safe and effective for postmenopausal hormone dependency breast cancer patients, further study and large-scale, high quality research is expected for further evaluation.